Identification and Root Cause Analysis of the Visible Particles Commonly Encountered in the Biopharmaceutical Industry | PDA Journal of Pharmaceutical Science and Technology

References

1.↵
1. Cromwell M. E. M.,
2. Hilario E.,
3. Jacobson F.
Protein Aggregation and Bioprocessing. AAPS J. 2006, 8 (3), E572–E579.
OpenUrl CrossRef PubMed Web of Science Google Scholar
2.↵
1. Das T. K.
Protein Particulate Detection Issues in Biotherapeutics Development—Current Status. AAPS PharmSciTech 2012, 13 (2), 732–746.
OpenUrl CrossRef PubMed Google Scholar
3.↵
1. Doessegger L.,
2. Mahler H.-C.,
3. Szczesny P.,
4. Rockstroh H.,
5. Kallmeyer G.,
6. Langenkamp A.,
7. Herrmann J.,
8. Famulare J.
The Potential Clinical Relevance of Visible Particles in Parenteral Drugs. J. Pharm. Sci. 2012, 101 (8), 2635–2644.
OpenUrl PubMed Google Scholar
4.↵
1. Mahler H.-C.,
2. Friess W.,
3. Grauschopf U.,
4. Kiese S.
Protein Aggregation: Pathways, Induction Factors and Analysis. J. Pharm. Sci. 2009, 98 (9), 2909–2934.
OpenUrl CrossRef PubMed Google Scholar
5.↵
1. Mathonet S.,
2. Mahler H.-C.,
3. Esswein S. T.,
4. Mazaheri M.,
5. Cash P. W.,
6. Wuchner K.,
7. Kallmeyer G.,
8. Das T. K.,
9. Finkler C.,
10. Lennard A.
A Biopharmaceutical Industry Perspective on the Control of Visible Particles in Biotechnology-Derived Injectable Drug Products. PDA J. Pharm. Sci. Technol. 2016, 70 (4), 392–408.
OpenUrl Abstract/FREE Full Text Google Scholar
6.↵
1. Bukofzer S.,
2. Ayres J.,
3. Chavez A.,
4. Devera M.,
5. Miller J.,
6. Ross D.,
7. Shabushnig J.,
8. Vargo S.,
9. Watson H.,
10. Watson R.
Industry Perspective on the Medical Risk of Visible Particles in Injectable Drug Products. PDA J. Pharm. Sci. Technol. 2015, 69 (1), 123–139.
OpenUrl FREE Full Text Google Scholar
7.↵
1. Cao X.,
2. Masatani P.,
3. Torraca G.,
4. Wen Z.-Q.
Identification of a Mixed Microparticle by Combined Microspectroscopic Techniques: A Real Forensic Case Study in the Biopharmaceutical Industry. Appl. Spectrosc. 2010, 64 (8), 895–900.
OpenUrl CrossRef PubMed Google Scholar
8.↵
1. Anger S.,
2. Begat C.,
3. Crnko V.,
4. Fantozzi G.,
5. Farach W.,
6. Fitzpatrick S.,
7. Gallagher B.,
8. Huelsmann S.,
9. Kinsey P.,
10. Langlade V.,
11. Lefevre G.,
12. Legendre E.,
13. McLean K.,
14. Miller J.,
15. Patel R.,
16. Perry A.,
17. Soukiassian H.,
18. Stanton A.,
19. Streich D.,
20. Timmons C.,
21. Vaneylen D.,
22. van Hoose T.,
23. Wildling L.,
24. Windover M.
Points to Consider: Best Practices to Identify Particle Entry Routes Along the Manufacturing Process for Parenteral Formulations. PDA J. Pharm. Sci. Technol. 2019, 73 (6), 635–647.
OpenUrl Abstract/FREE Full Text Google Scholar
9.↵
U.S. Pharmacopeial Convention. General Chapter <1787> Measurement of Subvisible Particulate Matter in Therapeutic Protein Injections. In USP 43—NF 38, USP: Rockville, MD, 2021.
Google Scholar
10.↵
1. Cao X.,
2. Stimpfl G.,
3. Wen Z.-Q.,
4. Frank G.,
5. Hunter G.
Identification and Root Cause Analysis of Cell Culture Media Precipitates in the Viral Deactivation Treatment with High-Temperature/Short-Time Method. PDA J. Pharm. Sci. Technol. 2013, 67 (1), 63–73.
OpenUrl Abstract/FREE Full Text Google Scholar
11.↵
1. Hindelang F.,
2. Roggo Y.,
3. Zurbach R.
Forensic Investigation in the Pharmaceutical Industry: Identification Procedure of Visible Particles in (Drug) Solutions and Different Containers by Combining Vibrational and X-Ray Spectroscopic Techniques. J. Pharm. Biomed. Anal. 2018, 148 334–349.
OpenUrl PubMed Google Scholar
12.↵
1. Causin V.,
2. Marega C.,
3. Guzzini G.,
4. Marigo A.
Forensic Analysis of Poly(Ethylene Terephthalate) Fibers by Infrared Spectroscopy. Appl. Spectrosc. 2004, 58 (11), 1272–1276.
OpenUrl CrossRef PubMed Google Scholar
13.↵
1. Cao X.,
2. Wen Z.-Q.,
3. Vance A.,
4. Torraca G.
Raman Microscopic Applications in the Biopharmaceutical Industry: In Situ Identification of Foreign Particulates inside Glass Containers with Aqueous Formulated Solutions. Appl. Spectrosc. 2009, 63 (7), 830–834.
OpenUrl CrossRef PubMed Google Scholar
14.↵
1. Cao X.,
2. Loussaert J. A.,
3. Wen Z-Q.
Microspectroscopic Investigation of the Membrane Clogging During the Sterile Filtration of the Growth Media for Mammalian Cell Culture. J. Pharm. Biomed. Anal. 2016, 119 10–15.
OpenUrl PubMed Google Scholar
15.↵
1. Jameel F.,
2. Skoug J. W.,
3. Nesbitt R. R.
1. Messick S.,
2. Saggu M.,
3. Ríos Quiroz A.
Chapter 11: Particles in Biopharmaceuticals: Causes, Characterization, and Strategy. In Development of Biopharmaceutical Drug-Device Products, Jameel F., Skoug J. W., Nesbitt R. R., Eds.; AAPS Advances in the Pharmaceutical Sciences Series, Vol 35; Springer International Publishing: Cham, 2020; pp 251–264.
Google Scholar
16.↵
1. Brown A. E.,
2. Reinhart K. A.
Polyester Fiber: From Its Invention to Its Present Position. Science 1971, 173 (3994), 287–293.
OpenUrl Abstract/FREE Full Text Google Scholar
17.↵
1. Shit S. C.,
2. Shah P.
A Review on Silicone Rubber. Natl. Acad. Sci. Lett. 2013, 36 (4), 355–365.
OpenUrl CrossRef Google Scholar
18.↵
1. Saller V.,
2. Matilainen J.,
3. Grauschopf U.,
4. Bechtold-Peters K.,
5. Mahler H.-C.,
6. Friess W.
Particle Shedding from Peristaltic Pump Tubing in Biopharmaceutical Drug Product Manufacturing. J. Pharm. Sci. 2015, 104 (4), 1440–1450.
OpenUrl PubMed Google Scholar
19.↵
1. Gerhardt A.,
2. Mcgraw N. R.,
3. Schwartz D. K.,
4. Bee J. S.,
5. Carpenter J. F.,
6. Randolph T. W.
Protein Aggregation and Particle Formation in Prefilled Glass Syringes. J. Pharm. Sci. 2014, 103 (6), 1601–1612.
OpenUrl PubMed Google Scholar
20.↵
1. Gerhardt A.,
2. Nguyen B. H.,
3. Lewus R.,
4. Carpenter J. F.,
5. Randolph T. W.
Effect of the Siliconization Method on Particle Generation in a Monoclonal Antibody Formulation in Pre-Filled Syringes. J. Pharm. Sci. 2015, 104 (5), 1601–1609.
OpenUrl PubMed Google Scholar
21.↵
1. Jezek J.,
2. Darton N. J.,
3. Derham B. K.,
4. Royle N.,
5. Simpson I.
Biopharmaceutical Formulations for Pre-Filled Delivery Devices. Expert Opin. Drug Delivery 2013, 10 (6), 811–828.
OpenUrl Google Scholar
22.↵
1. Gilbert C. R.,
2. Haouzi P.
Particle Size, Distribution, and Behavior of Talc Preparations: Within the United States and Beyond. Curr. Opin. Pulm. Med. 2019, 25 (4), 1531–6971.
OpenUrl Google Scholar
23.↵
1. Kopp M. R. G.,
2. Grigolato F.,
3. Zürcher D.,
4. Das T. K.,
5. Chou D.,
6. Wuchner K.,
7. Arosio P.
Surface-Induced Protein Aggregation and Particle Formation in Biologics: Current Understanding of Mechanisms, Detection and Mitigation Strategies. J. Pharm. Sci 2023, 112 (2), 377–385.
OpenUrl CrossRef PubMed Google Scholar
24.↵
U.S. Food and Drug Administration, Guidance for Industry: Container Closure Systems for Packaging Human Drugs and Biologics. Center for Drug Evaluation and Research, U.S. Department of Health and Human Services: Rockville, MD, 1999.
Google Scholar
25.↵
International Conference for Harmonisation, Quality Guideline Q1A(R2): Stability Testing of New Drug Substances and Products. ICH: Geneva, 2003.
Google Scholar
26.↵
1. Carter S. M.,
2. Granchelli J.
Thermo Scientific Nalgene PETG Bottle Performance at −70°C. ThermoFisher Scientific, 2021.
Google Scholar
27.↵
1. Sacha G. A.,
2. Saffell-Clemmer W.,
3. Abram K.,
4. Akers M. J.
Practical Fundamentals of Glass, Rubber, and Plastic Sterile Packaging Systems. Pharm. Dev. Technol. 2010, 15 (1), 6–34.
OpenUrl PubMed Google Scholar
28.↵
U.S. Pharmacopeial Convention. General Chapter <1660> Evaluation of the Inner Surface Durability of Glass Containers. In USP 43—NF 38, USP: Rockville, MD, 2019.
Google Scholar
29.↵
U.S. Pharmacopeial Convention. General Chapter <660> Containers—Glass. In USP 43—NF 38, USP: Rockville, MD, 2019
Google Scholar
30.↵
1. Langille S. E.
Particulate Matter in Injectable Drug Products. PDA J. Pharm. Sci. Technol. 2013, 67 (3), 186–200.
OpenUrl Abstract/FREE Full Text Google Scholar
31.↵
1. Timmons C. L.,
2. Liu C. Y.,
3. Merkle S.
Particulate Generation Mechanisms During Bulk Filling and Mitigation Via New Glass Vial. PDA J. Pharm. Sci. Technol. 2017, 71 (5), 379–392.
OpenUrl Abstract/FREE Full Text Google Scholar
32.↵
1. Ennis R. D.,
2. Pritchard R.,
3. Nakamura C.,
4. Coulon M.,
5. Yang T.,
6. Visor G. C.,
7. Lee W. A.
Glass Vials for Small Volume Parenterals: Influence of Drug and Manufacturing Processes on Glass Delamination. Pharm. Dev. Technol. 2001, 6 (3), 393–405.
OpenUrl PubMed Google Scholar
33.↵
1. Iacocca R. G.,
2. Allgeier M.
Corrosive Attack of Glass by a Pharmaceutical Compound. J. Mater. Sci. 2007, 42 (3), 801–811.
OpenUrl Google Scholar
34.↵
1. Schwarzenbach M. S.,
2. Reimann P.,
3. Thommen V.,
4. Hegner M.,
5. Mumenthaler M.,
6. Schwob J.,
7. Güntherodt H.-J.
Topological Structure and Chemical Composition of Inner Surfaces of Borosilicate Vials. PDA J. Pharm. Sci. Technol. 2004, 58 (3), 169–175.
OpenUrl Abstract/FREE Full Text Google Scholar
35.↵
1. Ratnaswamy G.,
2. Hair A.,
3. Li G.,
4. Thirumangalathu R.,
5. Nashed-Samuel Y.,
6. Brych L.,
7. Dharmavaram V.,
8. Wen Z.-Q.,
9. Fujimori K.,
10. Jing W.,
11. Sethuraman A.,
12. Swift R.,
13. Ricci M. S.,
14. Piedmonte D. M.
A Case Study of Nondelamination Glass Dissolution Resulting in Visible Particles: Implications for Neutral pH Formulations. J. Pharm. Sci. 2014, 103 (4), 1104–1114.
OpenUrl PubMed Google Scholar
36.↵
1. Tyagi A. K.,
2. Banerjee S.
1. Sengupta P.
Natural Glasses Under Extreme Conditions. In Materials under Extreme Conditions: Recent Trends and Future Prospects; Tyagi A. K., Banerjee S. Eds.; Elsevier, 2017; pp 235–258.
Google Scholar
37.↵
1. Jones L. S.,
2. Kaufmann A.,
3. Middaugh C. R.
Silicone Oil Induced Aggregation of Proteins. J. Pharm. Sci. 2005, 94 (4), 918–927.
OpenUrl CrossRef PubMed Google Scholar
38.↵
1. Mizutani T.
Estimation of Protein and Drug Adsorption onto Silicone-Coated Glass Surfaces. J. Pharm. Sci. 1981, 70 (5), 493–496.
OpenUrl CrossRef PubMed Web of Science Google Scholar
39.↵
1. Basu P.,
2. Krishnan S.,
3. Thirumangalathu R.,
4. Randolph T. W.,
5. Carpenter J. F.
IgG1 Aggregation and Particle Formation Induced by Silicone-Water Interfaces on Siliconized Borosilicate Glass Beads: A Model for Siliconized Primary Containers. J. Pharm. Sci. 2013, 102 (3), 852–865.
OpenUrl PubMed Google Scholar
40.↵
1. Kasimbeg P. N. O.,
2. Cheong F. C.,
3. Ruffner D. B.,
4. Blusewicz J. M.,
5. Philips L. A.
Holographic Characterization of Protein Aggregates in the Presence of Silicone Oil and Surfactants. J. Pharm. Sci. 2019, 108 (1), 155–161.
OpenUrl PubMed Google Scholar
41.↵
1. Lankers M.,
2. Munhall J.,
3. Valet O.
Differentiation between Foreign Particulate Matter and Silicone Oil Induced Protein Aggregation in Drug Solutions by Automated Raman Spectroscopy. Microsc. Microanal. 2008, 14 (S2), 1612–1613.
OpenUrl Google Scholar
42.↵
1. Wang W.,
2. Ignatius A. A.,
3. Thakkar S. V.
Impact of Residual Impurities and Contaminants on Protein Stability. J. Pharm. Sci. 2014, 103 (5), 1315–1330.
OpenUrl PubMed Google Scholar
43.↵
1. Li J.,
2. Pinnamaneni S.,
3. Quan Y.,
4. Jaiswal A.,
5. Andersson F. I.,
6. Zhang X.
Mechanistic Understanding of Protein-Silicone Oil Interactions. Pharm. Res. 2012, 29 (6), 1689–1697.
OpenUrl CrossRef PubMed Google Scholar
44.↵
1. Mathaes R.,
2. Mahler H.-C.,
3. Buettiker J.-P.,
4. Roehl H.,
5. Lam P.,
6. Brown H.,
7. Luemkemann J.,
8. Adler M.,
9. Huwyler J.,
10. Streubel A.,
11. Mohl S.
The Pharmaceutical Vial Capping Process: Container Closure Systems, Capping Equipment, Regulatory Framework, and Seal Quality Tests. Eur. J. Pharm. Biopharm. 2016, 99, 54–64.
OpenUrl PubMed Google Scholar
45.↵
1. Hecker A.,
2. Di Maro A.,
3. Liechti E. F.,
4. Klenke F. M.
Avoiding Unconscious Injection of Vial-Derived Rubber Particles During Intra-Articular Drug Administration. Osteoarthritis and Cartilage Open 2021, 3 (2), 100164.
OpenUrl Google Scholar
46.↵
1. Rathore N.,
2. Rajan R. S.
Current Perspectives on Stability of Protein Drug Products During Formulation, Fill and Finish Operations. Biotechnol. Prog. 2008, 24 (3), 504–514.
OpenUrl PubMed Google Scholar
47.↵
1. Wang W.
Instability, Stabilization, and Formulation of Liquid Protein Pharmaceuticals. Int. J. Pharm. 1999, 185 (2), 129–188.
OpenUrl CrossRef PubMed Web of Science Google Scholar
48.↵
1. Wang W.,
2. Singh S.,
3. Zeng D. L.,
4. King K.,
5. Nema S.
Antibody Structure, Instability, and Formulation. J. Pharm. Sci. 2007, 96 (1), 1–26.
OpenUrl CrossRef PubMed Google Scholar
49.↵
1. Sharma B.
Immunogenicity of Therapeutic Proteins. Part 1: Impact of Product Handling. Biotechnol. Adv. 2007, 25 (3), 310–317.
OpenUrl CrossRef PubMed Web of Science Google Scholar
50.↵
1. Sharma B.
Immunogenicity of Therapeutic Proteins. Part 2: Impact of Container Closures. Biotechnol. Adv. 2007, 25 (3), 318–324.
OpenUrl CrossRef PubMed Web of Science Google Scholar
51.↵
1. Sharma B.
Immunogenicity of Therapeutic Proteins. Part 3: Impact of Manufacturing Changes. Biotechnol. Adv. 2007, 25 (3), 325–331.
OpenUrl CrossRef PubMed Google Scholar
52.↵
1. Thurow H.,
2. Geisen K.
Stabilisation of Dissolved Proteins against Denaturation at Hydrophobic Interfaces. Diabetologia 1984, 27 (2), 212–218.
OpenUrl PubMed Google Scholar
53.↵
1. Zhou S.,
2. Schöneich C.,
3. Singh S. K.
Biologics Formulation Factors Affecting Metal Leachables from Stainless Steel. AAPS PharmSciTech 2011, 12 (1), 411–421.
OpenUrl PubMed Google Scholar
54.↵
1. Chu G. C.,
2. Chelius D.,
3. Xiao G.,
4. Khor H. K.,
5. Coulibaly S.,
6. Bondarenko P. V.
Accumulation of Succinimide in a Recombinant Monoclonal Antibody in Mildly Acidic Buffers under Elevated Temperatures. Pharm. Res. 2007, 24 (6), 1145–1156.
OpenUrl PubMed Google Scholar
55.↵
1. Dolník V.
Capillary Electrophoresis of Proteins 2003–2005. Electrophoresis 2006, 27 (1), 126–141.
OpenUrl CrossRef PubMed Web of Science Google Scholar
56.↵
1. Gadgil H. S.,
2. Bondarenko P. V.,
3. Pipes G.,
4. Rehder D.,
5. McAuley A.,
6. Perico N.,
7. Dillon T.,
8. Ricci M.,
9. Treuheit M.
The LC/MS Analysis of Glycation of IGG Molecules in Sucrose Containing Formulations. J. Pharm. Sci. 2007, 96 (10), 2607–2621.
OpenUrl CrossRef PubMed Web of Science Google Scholar
57.↵
1. Harris R. J.,
2. Kabakoff B.,
3. Macchi F. D.,
4. Shen F. J.,
5. Kwong M.,
6. Andya J. D.,
7. Shire S. J.,
8. Bjork N.,
9. Totpal K.,
10. Chen A. B.
Identification of Multiple Sources of Charge Heterogeneity in a Recombinant Antibody. J. Chromatogr. B: Biomed. Sci. Appl. 2001, 752 (2), 233–245.
OpenUrl CrossRef PubMed Google Scholar
58.↵
1. Leiske D. L.,
2. Shieh I. C.,
3. Tse M. L.
A Method to Measure Protein Unfolding at an Air–Liquid Interface. Langmuir 2016, 32 (39), 9930–9937.
OpenUrl PubMed Google Scholar
59.↵
1. Paul A. J.,
2. Bickel F.,
3. Röhm M.,
4. Hospach L.,
5. Halder B.,
6. Rettich N.,
7. Handrick R.,
8. Herold E. M.,
9. Kiefer H.,
10. Hesse F.
High-Throughput Analysis of Sub-Visible mAb Aggregate Particles Using Automated Fluorescence Microscopy Imaging. Anal. Bioanal. Chem. 2017, 409 (17), 4149–4156.
OpenUrl PubMed Google Scholar
60.↵
1. Shieh I. C.,
2. Patel A. R.
Predicting the Agitation-Induced Aggregation of Monoclonal Antibodies Using Surface Tensiometry. Mol. Pharmaceutics 2015, 12 (9), 3184–3193.
OpenUrl Google Scholar
61.↵
1. Lin G. L.,
2. Pathak J. A.,
3. Kim D. H.,
4. Carlson M.,
5. Riguero V.,
6. Kim Y. J.,
7. Buff J. S.,
8. Fuller G. G.
Interfacial Dilatational Deformation Accelerates Particle Formation in Monoclonal Antibody Solutions. Soft Matter 2016, 12 (14), 3293–3302.
OpenUrl PubMed Google Scholar
62.↵
1. Zhai J.,
2. Lee T.-H.,
3. Small D. H.,
4. Aguilar M.-I.
Characterization of Early Stage Intermediates in the Nucleation Phase of Abeta Aggregation. Biochemistry 2012, 51 (6), 1070–1078.
OpenUrl PubMed Google Scholar
63.↵
1. Rosenberg A. S.
Effects of Protein Aggregates: An Immunologic Perspective. AAPS J. 2006, 8 (3), E501–E507.
OpenUrl CrossRef PubMed Web of Science Google Scholar
64.↵
1. Shukla D.,
2. Schneider C. P.,
3. Trout B. L.
Molecular Level Insight into Intra-Solvent Interaction Effects on Protein Stability and Aggregation. Adv. Drug Delivery Rev. 2011, 63 (13), 1074–1085.
OpenUrl PubMed Google Scholar
65.↵
1. Wang W.
Protein Aggregation and Its Inhibition in Biopharmaceutics. Int. J. Pharm. 2005, 289 (1–2), 1–30.
OpenUrl CrossRef PubMed Web of Science Google Scholar
66.↵
1. Wang W.,
2. Roberts C. J.
Protein Aggregation – Mechanisms, Detection, and Control. Int. J. Pharm. 2018, 550 (1–2), 251–268.
OpenUrl PubMed Google Scholar
67.↵
1. Lins R. D.,
2. Pereira C. S.,
3. Hünenberger P. H.
Trehalose–Protein Interaction in Aqueous Solution. Proteins 2004, 55 (1), 177–186.
OpenUrl CrossRef PubMed Google Scholar
68.↵
1. Timasheff S. N.
Protein-Solvent Preferential Interactions, Protein Hydration, and the Modulation of Biochemical Reactions by Solvent Components. Proc. Natl. Acad. Sci. U.S.A. 2002, 99 (15), 9721–9726.
OpenUrl Abstract/FREE Full Text Google Scholar
69.↵
1. Warne N. W.,
2. Mahler H.-C.
1. Singh S. K.
Sucrose and Trehalose in Therapeutic Protein Formulations. In Challenges in Protein Product Development, Warne N. W., Mahler H.-C., Eds.; AAPS Advances in the Pharmaceutical Sciences Series, Vol. 38; Springer International Publishing: Cham, 2018; pp 63–95.
Google Scholar
70.↵
1. Wang B.,
2. Tchessalov S.,
3. Warne N. W.,
4. Pikal M. J.
Impact of Sucrose Level on Storage Stability of Proteins in Freeze-Dried Solids: I. Correlation of Protein–Sugar Interaction with Native Structure Preservation. J. Pharm. Sci. 2009, 98 (9), 3131–3144.
OpenUrl PubMed Google Scholar
71.↵
1. Israelachvili J. N.
Intermolecular and Surface Forces; Elsevier, 2011.
Google Scholar
72.↵
1. Chen C.-H.,
2. Yao T.,
3. Zhang Q.,
4. He Y.-M.,
5. Xu L.-H.,
6. Zheng M.,
7. Zhou G.-R.,
8. Zhang Y.,
9. Yang H.-J.,
10. Zhou P.
Influence of Trehalose on Human Islet Amyloid Polypeptide Fibrillation and Aggregation. RSC Adv. 2016, 6 (18), 15240–15246.
OpenUrl Google Scholar
73.↵
1. Liu L.,
2. Qi W.,
3. Schwartz D. K.,
4. Randolph T. W.,
5. Carpenter J. F.
The Effects of Excipients on Protein Aggregation During Agitation: An Interfacial Shear Rheology Study. J. Pharm. Sci. 2013, 102 (8), 2460–2470.
OpenUrl PubMed Google Scholar
74.↵
1. Abbas S. A.,
2. Sharma V. K.,
3. Patapoff T. W.,
4. Kalonia D. S.
Characterization of Antibody-Polyol Interactions by Static Light Scattering: Implications for Physical Stability of Protein Formulations. Int. J. Pharm. 2013, 448 (2), 382–389.
OpenUrl PubMed Google Scholar
75.↵
1. Lim J. Y.,
2. Kim N. A.,
3. Lim D. G.,
4. Eun C-y.,
5. Choi D.,
6. Jeong S. H.
Biophysical Stability of hyFc Fusion Protein with Regards to Buffers and Various Excipients. Int. J. Biol. Macromol. 2016, 86, 622–629.
OpenUrl PubMed Google Scholar
76.↵
1. Wen L.,
2. Zheng X.,
3. Wang X.,
4. Lan H.,
5. Yin Z.
Bilateral Effects of Excipients on Protein Stability: Preferential Interaction Type of Excipient and Surface Aromatic Hydrophobicity of Protein. Pharm. Res. 2017, 34 (7), 1378–1390.
OpenUrl PubMed Google Scholar
77.↵
1. Cao X.,
2. Fesinmeyer R. M.,
3. Pierini C. J.,
4. Siska C. C.,
5. Litowski J. R.,
6. Brych S.,
7. Wen Z.-Q.,
8. Kleemann G. R.
Free Fatty Acid Particles in Protein Formulations, Part 1: Microspectroscopic Identification. J. Pharm. Sci. 2015, 104 (2), 433–446.
OpenUrl PubMed Google Scholar
78.↵
1. Kerwin B. A.
Polysorbates 20 and 80 Used in the Formulation of Protein Biotherapeutics: Structure and Degradation Pathways. J. Pharm. Sci. 2008, 97 (8), 2924–2935.
OpenUrl CrossRef PubMed Google Scholar
79.↵
1. Katakam M.,
2. Bell L. N.,
3. Banga A. K.
Effect of Surfactants on the Physical Stability of Recombinant Human Growth Hormone. J. Pharm. Sci. 1995, 84 (6), 713–716.
OpenUrl CrossRef PubMed Web of Science Google Scholar
80.↵
1. Kishore R. S. K.,
2. Kiese S.,
3. Fischer S.,
4. Pappenberger A.,
5. Grauschopf U.,
6. Mahler H.-C.
The Degradation of Polysorbates 20 and 80 and Its Potential Impact on the Stability of Biotherapeutics. Pharm. Res. 2011, 28 (5), 1194–1210.
OpenUrl PubMed Google Scholar
81.↵
1. Maa Y.-F.,
2. Hsu C. C.
Investigation on Fouling Mechanisms for Recombinant Human Growth Hormone Sterile Filtration. J. Pharm. Sci. 1998, 87 (7), 808–812.
OpenUrl CrossRef PubMed Google Scholar
82.↵
1. Carpenter J. F.,
2. Manning M. C.
1. Randolph T. W.,
2. Jones L. S.
Surfactant-Protein Interactions. In Rational Design of Stable Protein Formulations: Theory and Practice; Carpenter J. F., Manning M. C., Eds.; Springer: New York, 2002; pp 159–175.
Google Scholar
83.↵
1. Himanen J.-P.,
2. Sarvas M.,
3. Helander I. M.
Assessment of Non-Protein Impurities in Potential Vaccine Proteins Produced by Bacillus subtilis. Vaccine 1993, 11 (9), 970–973.
OpenUrl CrossRef PubMed Google Scholar
84.↵
1. Johnston A.,
2. Uren E.,
3. Johnstone D.,
4. Wu J.
Low pH, Caprylate Incubation as a Second Viral Inactivation Step in the Manufacture of Albumin: Parametric and Validation Studies. Biologicals 2003, 31 (3), 213–221.
OpenUrl PubMed Google Scholar
85.↵
1. Tong H.-F.,
2. Lin D.-Q.,
3. Gao D.,
4. Yuan X.-M.,
5. Yao S.-J.
Caprylate as the Albumin-Selective Modifier to Improve IgG Purification with Hydrophobic Charge-Induction Chromatography. J. Chromatogr. A 2013, 1285, 88–96.
OpenUrl PubMed Google Scholar